¼¼°èÀÇ ÇØ¾ç ÀǾàǰ ½ÃÀå
Marine Pharmaceuticals
»óǰÄÚµå : 1577591
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 133 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,056,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,169,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÇØ¾ç ÀǾàǰ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 69¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸Á

2023³â 41¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÇØ¾ç ÀǾàǰ ¼¼°è ½ÃÀåÀº 2023-2030³â ºÐ¼® ±â°£ µ¿¾È ¿¬Æò±Õ 7.6% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 69¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Á¾¾çÇÐ ÃÖÁ¾ ¿ëµµ ºÎ¹®Àº CAGR 8.1%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ Á¾·á ½ÃÁ¡¿¡ 33¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÉÇ÷°ü°è ÃÖÁ¾ ¿ëµµ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 7.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀå 11¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.3%·Î ¼ºÀå Àü¸Á

¹Ì±¹ÀÇ ÇØ¾ç ÀǾàǰ ½ÃÀåÀº 2023³â 11¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 11¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³â ºÐ¼® ±â°£ µ¿¾È 7.3%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 7.0%¿Í 6.4%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¾à 6.0%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ÇØ¾çÀǾàǰ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

ÇØ¾ç ÀǾàǰÀ̶õ ¹«¾ùÀ̸ç, Çö´ë ÀÇÇп¡¼­ ¿Ö Áß¿äÇѰ¡?

ÇØ¾ç ÀǾàǰÀº ÇØÁ¶·ù, ÇØ¸éµ¿¹°, ¿¬Ã¼µ¿¹°, ¹ÚÅ׸®¾Æ µî ÇØ¾ç »ý¹°¿¡¼­ ÃßÃâÇÑ ÀǾàǰ ¹× Ä¡·á È­ÇÕ¹°À» ¸»ÇÕ´Ï´Ù. À̵é È­ÇÕ¹°Àº µ¶Æ¯ÇÑ È­ÇÐ ±¸Á¶¿Í »ý¹°ÇÐÀû Ȱ¼ºÀ» °¡Áö°í ÀÖ¾î ¾Ï, ¿°Áõ, °¨¿° µî ´Ù¾çÇÑ Áúº´À» Ä¡·áÇÏ´Â µ¥ À¯¿ëÇÕ´Ï´Ù. ÇØ¾ç ȯ°æ, ƯÈ÷ ½ÉÇØ ºÐÃⱸ¿Í »êÈ£ÃÊ¿Í °°Àº ±ØÇÑ È¯°æÀº »õ·Î¿î ¾à¹° È帷ΠÀáÀç·ÂÀ» Áö´Ñ »ý¹° Ȱ¼º ¹°ÁúÀÇ º¸°íÀÔ´Ï´Ù. ¿¬±¸ °³¹ßÀÚ¿Í Á¦¾à»çµéÀº º¸´Ù È¿°úÀûÀÎ »õ·Î¿î Ä¡·á¹ýÀ» ã±â À§ÇØ ÇØ¾ç »ý¹°¿¡ ÇÔÀ¯µÈ õ¿¬ È­ÇÕ¹°À» Ȱ¿ëÇÏ¿© µ¶Æ¯ÇÑ ÀÛ¿ë ±âÀüÀ» °¡Áø ¾à¹°À» °³¹ßÇϱâ À§ÇØ ÇØ¾ç »ý¹° ´Ù¾ç¼ºÀ» Á¡Á¡ ´õ ¸¹ÀÌ Å½»öÇϰí ÀÖ½À´Ï´Ù. ´ëÇ¥ÀûÀÎ ¿¹·Î´Â ¸¸¼º ÅëÁõ °ü¸®¿¡ »ç¿ëµÇ´Â µðÄÚ³ëŸÀ̵å¿Í Ç×¾ÏÁ¦ Æ®¶óº¤Å×µò°ú °°Àº ÇØ¾ç À¯·¡ ÀǾàǰÀ» µé ¼ö ÀÖ½À´Ï´Ù. ÇØ¾ç ÀÚ¿ø¿¡¼­ ½Å¾àÀ» ¹ß°ßÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀº »ý¸í°øÇÐ ¹× Á¦¾à »ê¾÷¿¡¼­ ÇØ¾ç ÀǾàǰÀ» À¯¸ÁÇÏ°í ºü¸£°Ô ¹ßÀüÇÒ ¼ö ÀÖ´Â ºÐ¾ß·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ÇØ¾ç ½Å¾à °³¹ßÀÇ °¡´É¼ºÀ» ¾î¶»°Ô ³ÐÈ÷°í Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº ÇØ¾ç ÀǾàǰÀÇ ¹ß°ß°ú °³¹ßÀÇ °¡´É¼ºÀ» Å©°Ô ³ÐÇôÁÖ¾ú½À´Ï´Ù. À¯ÀüüÇÐ, ´Ü¹éÁúüÇÐ, ´ë»çüÇÐ µî Ãֽбâ¼úÀ» ÅëÇØ °úÇÐÀÚµéÀº ºÐÀÚ ¼öÁØ¿¡¼­ ÇØ¾ç »ý¹° ´Ù¾ç¼ºÀ» Ž»öÇÏ°í »ý¹°ÇÐÀû Ȱ¼º È­ÇÕ¹°À» º¸´Ù È¿À²ÀûÀ¸·Î ½Äº°ÇÏ°í ºÐ¸®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ½ÉÇØ Ž»ç ±â¼ú°ú ¿ø°ÝÁ¶Á¾·Îº¿(ROV)ÀÇ °³¹ß·Î ¿¬±¸ÀÚµéÀº ÀÌÀü¿¡´Â Á¢±ÙÇÒ ¼ö ¾ø¾ú´ø ÇØ¾ç ȯ°æ¿¡ Á¢±ÙÇÒ ¼ö ÀÖ°Ô µÇ¾î µ¶Æ¯ÇÑ »ýÈ­ÇÐÀû Ư¼ºÀ» °¡Áø »õ·Î¿î »ý¹°Ã¼¸¦ ¹ß°ßÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀÌ ³ô¾ÆÁ³½À´Ï´Ù. ¶ÇÇÑ, °íó¸® ½ºÅ©¸®´×°ú ¹ÙÀÌ¿À ÇÁ·Î½ºÆåÆÃÀÇ ¹ßÀüÀ¸·Î ÇØ¾ç »ý¹°¿¡¼­ ½Å¾à Èĺ¸¹°ÁúÀÇ ¹ß±¼ÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇÕ¼º»ý¹°ÇÐ ¹× »ý¹°°øÇÐÀÇ Çõ½ÅÀº Á¦¾àȸ»çµéÀÌ ½ÇÇè½Ç¿¡¼­ ÇØ¾ç È­ÇÕ¹°À» ÀçÇöÇÏ¿© õ¿¬ ÇØ¾ç ÀÚ¿øÀ» °í°¥½ÃŰÁö ¾Ê°íµµ Áö¼Ó°¡´ÉÇÑ »ý»êÀ» º¸ÀåÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ ºñ¾àÀûÀÎ ¹ßÀüÀº ÇØ¾ç ÀǾàǰ °³¹ßÀÇ Áøº¸¸¦ ÃËÁøÇÏ°í ±âÁ¸ Ä¡·á¹ý¿¡ ³»¼ºÀ» º¸ÀÌ´Â Áúº´¿¡ ´ëÇÑ »õ·Î¿î Ä¡·á¹ýÀÇ ¹®À» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù.

Áö¼Ó°¡´É¼º°ú ±ÔÁ¦°¡ ÇØ¾ç ÀǾàǰÀÇ ¼ºÀå¿¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ÀǾàǰ °³¹ßÀ» À§ÇÑ ÇØ¾ç ȯ°æ Ž»ç´Â Áö¼Ó°¡´É¼º°ú ±ÔÁ¦¿¡ ´ëÇÑ Áß¿äÇÑ °í·Á»çÇ×À» Á¦±âÇÕ´Ï´Ù. ÀǾàǰ °³¹ßÀ» À§ÇÑ ÇØ¾ç»ý¹° äÃë´Â ƯÈ÷ »êÈ£Ãʳª ½ÉÇØ ȯ°æ°ú °°Àº Ãë¾àÇÑ »ýŰ迡¼­ »ýŰ迡 Å« ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Á¦¾àȸ»ç¿Í ¿¬±¸ÀÚµéÀº ¾ç½Ä, ÇÕ¼º »ý»ê, ¹Ì»ý¹° ¹ßÈ¿¸¦ ÅëÇÑ ÇØ¾ç È­ÇÕ¹° Á¶´Þ µî Áö¼Ó°¡´ÉÇÑ ¹æ¹ýÀ» äÅÃÇØ¾ß ÇÑ´Ù´Â ¾Ð·ÂÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇØ¾ç »ý¹° ½Ã·á¿¡ ´ëÇÑ ±ÔÁ¦°¡ ÁøÈ­Çϰí ÀÖÀ¸¸ç, °¢±¹Àº ¿µÇØ ³» ÇØ¾ç ÀÚ¿ø äÃ븦 ´õ¿í ¾ö°ÝÇÏ°Ô ±ÔÁ¦Çϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ¿ø¿¡ ´ëÇÑ Á¢±ÙÀ» ±ÔÁ¤ÇÏ´Â ³ª°í¾ß ÀÇÁ¤¼­¿Í °°Àº ±¹Á¦ Çù¾àÀº ÇØ¾ç ÀǾàǰ Ž»ç¸¦ µÑ·¯½Ñ Á¤Ã¥À» Çü¼ºÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ȯ°æ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ÃÖ¼ÒÈ­Çϸ鼭 À±¸®ÀûÀ̰í ÇÕ¹ýÀûÀ¸·Î ÇØ¾ç È­ÇÕ¹°À» ȹµæÇϱâ À§ÇØ ÀÌ·¯ÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¸¦ Àß È°¿ëÇØ¾ß ÇÕ´Ï´Ù.

ÇØ¾ç ÀǾàǰ ¼¼°è ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº?

¼¼°è ÇØ¾ç ÀǾàǰ ½ÃÀåÀÇ ¼ºÀåÀº ÇØ¾ç »ý¸í°øÇÐ ±â¼úÀÇ ¹ßÀü, ¿¬±¸ ÀÚ±ÝÀÇ Áõ°¡, Áúº´ ÅðÄ¡¸¦ À§ÇÑ ½Å¾à¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ »õ·Î¿î Ç×»ýÁ¦ ¹× Ç×¾ÏÁ¦ Ž»ö¿¡ ÀÖ¾î ÇØ¾çÀÌ »ý¹°ÇÐÀû Ȱ¼º È­ÇÕ¹°ÀÇ ¹Ì°³¹ß ¿øÃµÀ̶ó´Â ÀνÄÀÌ ³ô¾ÆÁø °ÍÀÌ ÁÖ¿ä ¼ºÀå ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÇÏÀ̽º·çDz ½ºÅ©¸®´×°ú ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º¿Í °°Àº ½Å¾à°³¹ß ±â¼úÀÇ ¹ßÀüÀ¸·Î ÇØ¾ç »ý¹°¿¡¼­ ÀáÀçÀûÀÎ ¾à¹° È常¦ ½±°Ô ã¾Æ³¾ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ¾àÁ¦ ³»¼º ÁúȯÀÇ Áõ°¡¿Í ´ëü ¿ä¹ýÀÇ Çʿ伺µµ ÇØ¾ç À¯·¡ ÀǾàǰ¿¡ ´ëÇÑ °ü½ÉÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Çаè, ¿¬±¸±â°ü, Á¦¾àȸ»ç °£ÀÇ °øµ¿¿¬±¸°¡ È®´ëµÇ¸é¼­ ÀÌ ºÐ¾ßÀÇ ±â¼ú Çõ½ÅÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. Á¤ºÎ ¹× ¹Î°£´Üü´Â ÇØ¾ç ½Å¾à°³¹ß ÇÁ·Î±×·¥¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇØ¾ç »ý¹° ´Ù¾ç¼ºÀÇ ÀáÀç·Â¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÇØ¾ç ÀǾàǰ ½ÃÀåÀº Áö¼ÓÀûÀ¸·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(ÁÖ¸ñ¹Þ´Â 43°³ ±â¾÷)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Marine Pharmaceuticals Market to Reach US$6.9 Billion by 2030

The global market for Marine Pharmaceuticals estimated at US$4.1 Billion in the year 2023, is expected to reach US$6.9 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2023-2030. Oncology End-Use, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Cardiovascular End-Use segment is estimated at 7.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 7.3% CAGR

The Marine Pharmaceuticals market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.0% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.

Global Marine Pharmaceuticals Market - Key Trends & Drivers Summarized

What Are Marine Pharmaceuticals, and Why Are They Important in Modern Medicine?

Marine pharmaceuticals refer to drugs and therapeutic compounds derived from marine organisms such as algae, sponges, mollusks, and bacteria. These compounds have unique chemical structures and biological activities that make them valuable for treating a wide range of diseases, including cancer, inflammation, and infectious diseases. Marine environments, particularly extreme habitats like deep-sea vents and coral reefs, have become a treasure trove of bioactive substances that offer potential as novel drug candidates. Researchers and pharmaceutical companies are increasingly exploring the ocean's biodiversity for new, more effective treatments, leveraging the natural compounds found in marine organisms to develop drugs with unique mechanisms of action. Some notable examples include marine-derived drugs like ziconotide, used for chronic pain management, and trabectedin, an anti-cancer agent. The potential for discovering novel drugs from marine resources has positioned marine pharmaceuticals as a promising and rapidly evolving field within the biotechnology and pharmaceutical industries.

How Are Technological Advancements Expanding Opportunities in Marine Drug Discovery?

Technological advancements have significantly expanded the possibilities for discovering and developing marine pharmaceuticals. Modern techniques like genomics, proteomics, and metabolomics allow scientists to explore marine biodiversity at a molecular level, identifying and isolating bioactive compounds more efficiently. The development of deep-sea exploration technology and remote-operated vehicles (ROVs) has also enabled researchers to access previously unreachable marine environments, increasing the potential for finding new organisms with unique biochemical properties. Furthermore, advancements in high-throughput screening and bioprospecting have accelerated the identification of drug candidates from marine organisms. Innovations in synthetic biology and bioengineering are also helping pharmaceutical companies recreate marine compounds in the laboratory, ensuring sustainable production without depleting natural marine resources. These technological breakthroughs are driving progress in marine drug development, opening the door to new treatments for diseases that are resistant to traditional therapies.

Why Are Sustainability and Regulation Crucial to the Growth of Marine Pharmaceuticals?

The exploration of marine environments for pharmaceutical development raises important sustainability and regulatory considerations. Harvesting marine organisms for drug development can have significant ecological impacts, particularly in fragile ecosystems such as coral reefs or deep-sea environments. As a result, there is increasing pressure on pharmaceutical companies and researchers to adopt sustainable practices, such as sourcing marine compounds through aquaculture, synthetic production, or microbial fermentation. Additionally, the regulation of marine bioprospecting is evolving, with countries enforcing stricter controls on the extraction of marine resources within their territorial waters. International agreements like the Nagoya Protocol, which governs access to genetic resources, are playing a key role in shaping the policies around marine pharmaceutical exploration. Companies must navigate these regulatory frameworks to ensure the ethical and legal acquisition of marine compounds while minimizing their environmental footprint.

What Is Driving the Growth of the Global Marine Pharmaceuticals Market?

The growth in the global marine pharmaceuticals market is driven by several factors, including advances in marine biotechnology, increased research funding, and the rising demand for novel drugs to combat diseases. One key growth driver is the growing recognition of the ocean as an untapped source of biologically active compounds, particularly in the search for new antibiotics and anti-cancer agents. Technological advancements in drug discovery, such as high-throughput screening and bioinformatics, are making it easier to identify potential drug candidates from marine organisms. The increasing prevalence of drug-resistant diseases and the need for alternative therapies are also fueling interest in marine-derived pharmaceuticals. Furthermore, the expansion of collaborative efforts between academic institutions, research organizations, and pharmaceutical companies is accelerating innovation in the field. Governments and private entities are increasing investments in marine drug discovery programs, further driving market growth. As awareness of marine biodiversity’s potential grows, the marine pharmaceuticals market is poised for continued expansion.

Select Competitors (Total 43 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â